Creo Medical Group PLC Posting of 2021 Annual Report and Accounts (8484M)
May 26 2022 - 1:01AM
UK Regulatory
TIDMCREO
RNS Number : 8484M
Creo Medical Group PLC
26 May 2022
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Posting of 2021 Annual Report and Accounts
Notice of Annual General Meeting
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, confirms that
the Annual Report and Accounts for the year ended 31 December 2021
("2021 Annual Report") and the Notice of the Company's Annual
General Meeting ("AGM") have now been published on the Company's
website at
https://creomedical.com/investors/reports-and-presentations/ , with
hard copies being posted to those shareholders who have not elected
to receive electronic communication from the Company.
The AGM will be held on Tuesday, 28 June 2022 at 10:00am at the
offices of Osborne Clarke, 2 Temple Back East, Temple Quay, Bristol
BS1 6EG and will consider the Resolutions set out in the Notice of
AGM. The Company's CEO, Craig Gulliford, will make a short
presentation at the meeting. No new material information will be
included within the presentation.
Shareholders are encouraged to vote by proxy at the AGM, which
can be done:
-- By completing, signing the enclosed Form of Proxy and returning it to Equiniti; or
-- In the case of CREST members, by utilising the CREST electronic proxy appointment service.
Proxy votes must be received no later than 10:00am on 24 June
2022. Shareholders are recommended to appoint the chair of the
meeting as their proxy rather than a named person, as any such
named person may not be permitted to attend the AGM in the event of
unforeseen circumstances (e.g. if they are required to self
isolate).
Voting will be conducted on each Resolution by way of a
poll.
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Numis Securities Limited (Joint
Broker)
Freddie Barnfield / James Black
/ Duncan Monteith +44 (0)20 7260 1000
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSAAMBTMTJTTRT
(END) Dow Jones Newswires
May 26, 2022 02:01 ET (06:01 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024